INTS

DENVER, Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock trading near its 52-week low, a relatively small trading float, more than 500,000 shares reported short, three Wall Street Buy ratings and a long-awaited brain-cancer data readout. The question is whether the clinical data can justify the attention. NeOnc is scheduled to release topline Phase 2a results from its NEO100-01 trial at 8:30 a.m. ET on Wednesday, August 12, evaluating intranasal NEO100 in patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. The compa

8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 StudyCash and cash equivalents of $9.5 million as of June 30, 2026Increased business development activitiesConference call begins at 8:00 a.m. Eastern time todaySHELTON, Conn., Aug. 11, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tum

10-Q - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

Company to hold a conference call at 8AM ET on August 11, 2026 to review results and provide a corporate updateSHELTON, Conn., Aug. 4, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on August 11, 2026.

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

First patients dosed in SwitzerlandSHELTON, Conn., July 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announces that new patients have been administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The trial (NCT06358573) analyzes INT230-6 given before administration of the standard-of-care neoadjuvant immuno-chemotherapy ("SOC") and the SOC alone by using a 2-cohor

S-8 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancerOver 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper publishedActive strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profileStrengthened balance sheet supporting disciplined clinical development strategySHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of c

8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

Company receives the Cancer Treatment Technology Innovator of the Year awardSHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Cancer Treatment Technology Innovator of the Year 2026 – USA award recipient.

8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

Cash and cash equivalents of $10.2 million as of March 31, 2026Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below)Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026SHELTON, Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotec

10-Q - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

DEFA14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

DEF 14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

Company receives the Platinum Award for Innovator in Biotech Solutions CategorySHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (NASDAQ:INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6.